296 results
Page 4 of 15
8-K
EX-10.4
v81my u06
29 May 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
2phcy7fspstytm6t
11 May 20
Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives
4:24pm
8-K
EX-99.1
oisrq3chtmpow oy
27 Apr 20
Entry into a Material Definitive Agreement
5:21pm
8-K
EX-10.1
peb 2tuhi
27 Apr 20
Entry into a Material Definitive Agreement
5:21pm
424B5
2aqe p339
24 Apr 20
Prospectus supplement for primary offering
5:11pm
8-K
EX-10.1
sb31 aykjbd9w1fb
31 Mar 20
Entry into a Material Definitive Agreement
9:03am
8-K
EX-10.2
ui5ehwtcct39xsn5
31 Mar 20
Entry into a Material Definitive Agreement
9:03am
424B5
u4xhb49q2sg96lt7ila
31 Mar 20
Prospectus supplement for primary offering
9:01am
8-K
EX-99.1
l54lw7int
28 Feb 20
Strong Q4 2019 revenue growth of 35% driven by a 39% increase in revenue from iCAD’s AI Cancer Detection segment
8:32am
8-K
EX-10.1
iwwv9hmg
17 Jan 20
Departure of Directors or Certain Officers
4:58pm
8-K
EX-99.1
jww182ldutcycfp6
30 Oct 19
Continued strong momentum for ProFound AI™ iCAD’s proprietary cancer detection AI technology
4:31pm
8-K
EX-99.1
vlpk7fycsl5fh6
2 Aug 19
Results of Operations and Financial Condition
4:21pm
8-K
EX-1.1
4bx wcakfqkw9
14 Jun 19
Entry into a Material Definitive Agreement
6:09am
424B5
asbc4tnvee4wuvu
14 Jun 19
Prospectus supplement for primary offering
12:00am